Abbisko Cayman Past Earnings Performance
Past criteria checks 0/6
Abbisko Cayman has been growing earnings at an average annual rate of 3.6%, while the Biotechs industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 23.4% per year.
Key information
3.6%
Earnings growth rate
88.8%
EPS growth rate
Biotechs Industry Growth | 11.0% |
Revenue growth rate | 23.4% |
Return on equity | -21.8% |
Net Margin | -2,264.3% |
Next Earnings Update | 12 Aug 2024 |
Recent past performance updates
Recent updates
Here's Why We're Not Too Worried About Abbisko Cayman's (HKG:2256) Cash Burn Situation
Apr 27An Intrinsic Calculation For Abbisko Cayman Limited (HKG:2256) Suggests It's 37% Undervalued
Jan 09Will Abbisko Cayman (HKG:2256) Spend Its Cash Wisely?
Nov 01We Think Abbisko Cayman (HKG:2256) Can Afford To Drive Business Growth
Jun 08Revenue & Expenses Breakdown
How Abbisko Cayman makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 19 | -432 | 96 | 434 |
30 Sep 23 | 19 | -457 | 102 | 429 |
30 Jun 23 | 19 | -483 | 108 | 424 |
31 Mar 23 | 10 | -489 | 113 | 402 |
31 Dec 22 | 0 | -496 | 118 | 379 |
30 Sep 22 | 11 | -1,075 | 129 | 342 |
30 Jun 22 | 23 | -1,654 | 140 | 306 |
31 Mar 22 | 23 | -1,797 | 144 | 268 |
31 Dec 21 | 23 | -1,810 | 125 | 226 |
31 Mar 21 | 7 | -774 | 26 | 155 |
31 Dec 20 | 0 | -707 | 21 | 133 |
31 Dec 19 | 4 | -134 | 22 | 81 |
Quality Earnings: 2256 is currently unprofitable.
Growing Profit Margin: 2256 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2256 is unprofitable, but has reduced losses over the past 5 years at a rate of 3.6% per year.
Accelerating Growth: Unable to compare 2256's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2256 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22.1%).
Return on Equity
High ROE: 2256 has a negative Return on Equity (-21.79%), as it is currently unprofitable.